These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19037249)

  • 1. Advanced glycation end-products suppress neuropilin-1 expression in podocytes.
    Bondeva T; Rüster C; Franke S; Hammerschmid E; Klagsbrun M; Cohen CD; Wolf G
    Kidney Int; 2009 Mar; 75(6):605-16. PubMed ID: 19037249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity.
    Bondeva T; Wolf G
    Am J Nephrol; 2009; 30(4):336-45. PubMed ID: 19590177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner.
    Bondeva T; Wojciech S; Wolf G
    Am J Physiol Renal Physiol; 2011 Oct; 301(4):F852-70. PubMed ID: 21734098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin protects podocytes from damage by advanced glycation end-products.
    Ruester C; Franke S; Bondeva T; Wolf G
    Nephron Exp Nephrol; 2011; 117(1):e21-30. PubMed ID: 20689331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
    Rüster C; Bondeva T; Franke S; Förster M; Wolf G
    Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products.
    McRobert EA; Bach LA
    Nephrology (Carlton); 2016 Jan; 21(1):13-20. PubMed ID: 26032400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression.
    Liebisch M; Bondeva T; Franke S; Daniel C; Amann K; Wolf G
    Kidney Int; 2014 Jul; 86(1):103-17. PubMed ID: 24476693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth arrest specific 2-like protein 1 expression is upregulated in podocytes through advanced glycation end-products.
    Liebisch M; Bondeva T; Franke S; Hause S; Wolf G
    Nephrol Dial Transplant; 2017 Apr; 32(4):641-653. PubMed ID: 27638909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
    Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
    Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor.
    Chuang PY; Yu Q; Fang W; Uribarri J; He JC
    Kidney Int; 2007 Oct; 72(8):965-76. PubMed ID: 17667983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival.
    Guan F; Villegas G; Teichman J; Mundel P; Tufro A
    Kidney Int; 2006 May; 69(9):1564-9. PubMed ID: 16541019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus.
    Chuang PY; Dai Y; Liu R; He H; Kretzler M; Jim B; Cohen CD; He JC
    PLoS One; 2011; 6(8):e23566. PubMed ID: 21858169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaphorin3a promotes advanced diabetic nephropathy.
    Aggarwal PK; Veron D; Thomas DB; Siegel D; Moeckel G; Kashgarian M; Tufro A
    Diabetes; 2015 May; 64(5):1743-59. PubMed ID: 25475434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced-glycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway.
    Hirasawa Y; Sakai T; Ito M; Yoshimura H; Feng Y; Nagamatsu T
    Eur J Pharmacol; 2011 Dec; 672(1-3):159-68. PubMed ID: 21989075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB.
    Zhao X; Chen Y; Tan X; Zhang L; Zhang H; Li Z; Liu S; Li R; Lin T; Liao R; Zhang Q; Dong W; Shi W; Liang X
    J Pathol; 2018 Jun; 245(2):235-248. PubMed ID: 29570219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
    Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
    Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of human keratinocyte mobility and proliferation by advanced glycation end products-modified BSA.
    Zhu P; Yang C; Chen LH; Ren M; Lao GJ; Yan L
    Arch Dermatol Res; 2011 Jul; 303(5):339-50. PubMed ID: 21132435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells.
    Yamagishi S; Inagaki Y; Okamoto T; Amano S; Koga K; Takeuchi M
    Kidney Int; 2003 Feb; 63(2):464-73. PubMed ID: 12631112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta.
    Kim YS; Kim BC; Song CY; Hong HK; Moon KC; Lee HS
    J Lab Clin Med; 2001 Jul; 138(1):59-68. PubMed ID: 11433229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy.
    Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Liu BC
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1140-8. PubMed ID: 25921580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.